Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–10. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Weber JS, O’Day S, Urba W, Powderly J, Nichol G, Yellin M, Snively J, Hersh E. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008;26(36):5950–5956. doi:10.1200/JCO.2008.16.1927</INTDOI>.
   PubMed Web of Science ®Google Scholar
• Garber K. Driving T-cell immunotherapy to solid tumors. Nat Biotechnol. 2018;36(3):215–219. doi:10.1038/nbt.4090.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–1517. doi:10.1056/NEJMoa1407222.
   PubMed Web of Science ®Google Scholar
• Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517–528. doi:10.1016/S0140-6736(14)61403-3.
   PubMed Web of Science ®Google Scholar
• D’Aloia MM, Zizzari IG, Sacchetti B, Pierelli L, Alimandi M. CAR-T cells: the long and winding road to solid tumors. Cell Death Dis. 2018;9(3):282. doi:10.1038/s41419-018-0278-6.
   PubMed Web of Science ®Google Scholar
• Mishra M, Jiang H, Chawsheen HA, Gerard M, Toledano MB, Wei Q. Nrf2-activated expression of sulfiredoxin contributes to urethane-induced lung tumorigenesis. Cancer Lett. 2018;432:216–226. doi:10.1016/j.canlet.2018.06.011.
   PubMed Web of Science ®Google Scholar
• Bos JL, Rehmann H, Wittinghofer A. GEFs and GAPs: critical elements in the control of small G proteins. Cell. 2007;129(5):865–877. doi:10.1016/j.cell.2007.05.018.
   PubMed Web of Science ®Google Scholar
• Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell. 2017;170(1):17–33. doi:10.1016/j.cell.2017.06.009.
   PubMed Web of Science ®Google Scholar
• Li S, Balmain A, Counter CM. A model for RAS mutation patterns in cancers: finding the sweet spot. Nat Rev Cancer. 2018;18(12):767–777. doi:10.1038/s41568-018-0076-6.
   PubMed Web of Science ®Google Scholar
• Marzinotto S, Sessa F, Franzoni A, Anselmi A, Gastaldo LR, Mason S, Damante G, Beltrami CA, Mariuzzi L. KRAS codons 12 and 13 mutation analysis: a comparative study between direct sequencing and a new sensitive real-time PCR assay. Sequencing. 2012;2011:e895709. doi:10.1155/2011/895709
   Google Scholar
• Birkeland E, Wik E, Mjøs S, Hoivik EA, Trovik J, Werner HMJ, Kusonmano K, Petersen K, Raeder MB, Holst F, et al. KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. Br J Cancer. 2012;107(12):1997–2004. doi:10.1038/bjc.2012.477.
   PubMed Web of Science ®Google Scholar
• Cafri G, Yossef R, Pasetto A, Deniger DC, Lu Y-C, Parkhurst M, Gartner JJ, Jia L, Ray S, Ngo LT, et al. Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. Nature commun. 2019;10(1):449. doi:10.1038/s41467-019-08304-z.
   PubMed Web of Science ®Google Scholar
• Tran E, Robbins PF, Lu Y-C, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, et al. T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med. 2016;375(23):2255–2262. doi:10.1056/NEJMoa1609279.
   PubMed Web of Science ®Google Scholar
• Wang QJ, Yu Z, Griffith K, Hanada K, Restifo NP, Yang JC. Identification of T-cell receptors targeting KRAS-mutated human tumors. Cancer Immunol Res. 2016;4(3):204–214. doi:10.1158/2326-6066.CIR-15-0188.
   PubMed Web of Science ®Google Scholar
• Yossef R, Tran E, Deniger DC, Gros A, Pasetto A, Parkhurst MR, Gartner JJ, Prickett TD, Cafri G, Robbins PF, et al. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy. JCI Insight. 2018;3(19). doi:10.1172/jci.insight.122467.
   PubMed Web of Science ®Google Scholar
• Veatch JR, Jesernig BL, Kargl J, Fitzgibbon M, Lee SM, Baik C, Martins R, Houghton AM, Riddell SR. Endogenous CD4(+) T cells recognize neoantigens in lung cancer patients, including recurrent oncogenic KRAS and ERBB2 (Her2) driver mutations. Cancer Immunol Res. May 1 2019. doi:10.1158/2326-6066.cir-18-0402.
   PubMed Web of Science ®Google Scholar
• Gjertsen MK, Bakka A, Breivik J, Saeterdal I, Solheim BG, Soreide O, Thorsby E, Gaudernack G. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet. 1995;346(8987):1399–1400. doi:10.1016/s0140-6736(95)92408-6.
   PubMed Web of Science ®Google Scholar
• Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, et al. Kirsten ras mutations in patients with colorectal cancer: the “RASCAL II” study. Br J Cancer. 2001;85(5):692–696. doi:10.1054/bjoc.2001.1964.
   PubMed Web of Science ®Google Scholar
• Gjertsen MK, Saeterdal I, Saeboe-Larssen S, Gaudernack G. HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes. J Mol Med. 2003;81(1):43–50. doi:10.1007/s00109-002-0390-y</INTDOI>.
   PubMed Web of Science ®Google Scholar
• Wedén S, Klemp M, Gladhaug IP, Møller M, Eriksen JA, Gaudernack G, Buanes T. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer. 2011;128(5):1120–1128. doi:10.1002/ijc.25449.
   PubMed Web of Science ®Google Scholar
• Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Søreide O, Eriksen JA, Møller M, Baksaas I, Lothe RA, et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer. 2001;92(3):441–450. doi:10.1002/ijc.1205.
   PubMed Web of Science ®Google Scholar
• Chatani PD, Yang JC. Mutated RAS: targeting the “Untargetable” with T cells. Clin Cancer Res. 2020;26(3):537–544. doi:10.1158/1078-0432.CCR-19-2138.
   PubMed Web of Science ®Google Scholar
• Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114(3):535–546. doi:10.1182/blood-2009-03-211714.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013;36(2):133–151. doi:10.1097/CJI.0b013e3182829903.
   PubMed Web of Science ®Google Scholar
• Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122(6):863–871. doi:10.1182/blood-2013-03-490565.
   PubMed Web of Science ®Google Scholar
• Sim MJW, Lu J, Spencer M, Hopkins F, Tran E, Rosenberg SA, Long EO, Sun PD. High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D. Proc Natl Acad Sci U S A. 2020;117(23):12826–12835. doi:10.1073/pnas.1921964117.
   PubMed Web of Science ®Google Scholar
• Inderberg EM, Walchli S. Long-term surviving cancer patients as a source of therapeutic TCR. Cancer Immunol Immunother. 2020;69(5):859–865. doi:10.1007/s00262-019-02468-9.
   PubMed Web of Science ®Google Scholar
• Inderberg EM, Walchli S, Myhre MR, Trachsel S, Almasbak H, Kvalheim G, Gaudernack G. T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth. Oncoimmunology. 2017;6(4):e1302631. doi:10.1080/2162402X.2017.1302631.
   PubMed Web of Science ®Google Scholar
• Tateishi M, Saito I, Yamamoto K, Miyasaka N. Spontaneous production of epstein-barr virus by b lymphoblastoid cell lines obtained from patients with sjögren’s syndrome. possible involvement of a novel strain of epstein-barr virus in disease pathogenesis. Arthritis Rheum. 1993;36(6):827–835. doi:10.1002/art.1780360614.
   PubMed Web of Science ®Google Scholar
• Gjertsen MK, Bjorheim J, Saeterdal I, Myklebust J, Gaudernack G. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer. 1997;72(5):784–790. doi:10.1002/(sici)1097-0215(19970904)72:5<784::aid-ijc14>3.0.co;2-9.
   PubMed Web of Science ®Google Scholar
• Walchli S, Loset GA, Kumari S, Johansen JN, Yang W, Sandlie I, Olweus J. A practical approach to T-cell receptor cloning and expression. PLoS One. 2011;6(11):e27930. doi:10.1371/journal.pone.0027930.
   PubMed Web of Science ®Google Scholar
• Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, Boutselakis H, Cole CG, Creatore C, Dawson E, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47(D1):D941–D947. doi:10.1093/nar/gky1015.
   PubMed Web of Science ®Google Scholar
• Norell H, Zhang Y, McCracken J, Martins Da Palma T, Lesher A, Liu Y, Roszkowski JJ, Temple A, Callender GG, Clay T, et al. CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting. Cancer Immunol Immunother. 2010;59(6):851–862. doi:10.1007/s00262-009-0810-8.
   PubMed Web of Science ®Google Scholar
• Inderberg-Suso EM, Trachsel S, Lislerud K, Rasmussen AM, Gaudernack G. Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001. Oncoimmunology. 2012;1(5):670–686. doi:10.4161/onci.20426.
   PubMed Web of Science ®Google Scholar
• Houts PS, Lenhard RE, Varricchio C. ACS cancer facts and figures. Cancer Pract. 2000;8(3):105–108. doi:10.1046/j.1523-5394.2000.83001.x.
   Google Scholar
• Hou B, Tang Y, Li W, Zeng Q, Chang D. Efficiency of CAR-T therapy for treatment of solid tumor in clinical trials: a meta-analysis. Dis Markers. 2019;2019:3425291. doi:10.1155/2019/3425291.
   PubMed Web of Science ®Google Scholar
• Zacharakis N, Chinnasamy H, Black M, Xu H, Lu Y-C, Zheng Z, Pasetto A, Langhan M, Shelton T, Prickett T, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med. 2018;24(6):724–730. doi:10.1038/s41591-018-0040-8.
   PubMed Web of Science ®Google Scholar
• Stone JD, Harris DT, Kranz DM. TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity. Curr Opin Immunol. 2015;33:16–22. doi:10.1016/j.coi.2015.01.003.
   PubMed Web of Science ®Google Scholar
• Pandha H, Rigg A, John J, Lemoine N. Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell lines. Clin Exp Immunol. 2007;148(1):127–135. doi:10.1111/j.1365-2249.2006.03289.x.
   PubMed Web of Science ®Google Scholar
• Johnson AM, Bullock BL, Neuwelt AJ, Poczobutt JM, Kaspar RE, Li HY, Kwak JW, Hopp K, Weiser-Evans MCM, Heasley LE, et al. Cancer cell–intrinsic expression of MHC Class II regulates the immune microenvironment and response to Anti–PD-1 therapy in lung adenocarcinoma. J Immunol. 2020;204(8):2295–2307. doi:10.4049/jimmunol.1900778.
   PubMed Web of Science ®Google Scholar
• Hillig RC, Sautier B, Schroeder J, Moosmayer D, Hilpmann A, Stegmann CM, Werbeck ND, Briem H, Boemer U, Weiske J, et al. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction. Proc Natl Acad Sci U S A. 2019;116(7):2551–2560. doi:10.1073/pnas.1812963116.
   PubMed Web of Science ®Google Scholar
• Cafri G, Gartner JJ, Zaks T, Hopson K, Levin N, Paria BC, Parkhurst MR, Yossef R, Lowery FJ, Jafferji MS, et al. mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J Clin Invest. 2020;130(11):5976–5988. doi:10.1172/JCI134915.
   PubMed Web of Science ®Google Scholar